 |
市場調查報告書
商品編碼
1411694
糖尿病黃斑部水腫治療市場：依治療方法、最終用戶分類 - 全球預測 2024-2030Diabetic Macular Edema Treatment Market by Treatment (Corticosteroid Injections, Drugs, Laser Treatment), End-User (Hospitals, Ophthalmology Clinics) - Global Forecast 2024-2030 |
||||||
價格
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年糖尿病黃斑部水腫治療市場規模為29.7億美元，預計2024年將達31.2億美元，2030年預計將達42.2億美元，複合年成長率為5.11%。
糖尿病黃斑部水腫治療的全球市場
| 主要市場統計 | |
|---|---|
| 基準年[2023] | 29.7億美元 |
| 預測年份 [2024] | 31.2億美元 |
| 預測年份 [2030] | 42.2億美元 |
| 複合年成長率（%） | 5.11% |
FPNV定位矩陣
FPNV定位矩陣對於評估糖尿病黃斑部水腫治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。
市場佔有率分析
市場佔有率分析是一種綜合工具，可以對糖尿病黃斑部水腫治療市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。
該報告對以下幾個方面提供了寶貴的見解：
1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。
2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。
3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4-競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。
本報告解決了以下關鍵問題：
1-糖尿病黃斑部水腫治療市場的市場規模與預測是多少？
2-在糖尿病黃斑部水腫治療市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？
3-糖尿病黃斑部水腫治療市場的技術趨勢和法律規範是什麼？
4-糖尿病黃斑部水腫治療市場主要供應商的市場佔有率是多少？
5-進入糖尿病黃斑部水腫治療市場的合適型態和策略手段是什麼？
目錄
第1章 前言
第2章調查方法
第3章執行摘要
第4章市場概況
第5章市場洞察
- 市場動態
- 促進因素
- 隨著老年人口的增加，全球糖尿病盛行率正在上升
- 提高對糖尿病視網膜病變和糖尿病黃斑部水腫的認知
- 政府主導的提高對糖尿病視網膜病變認知的舉措
- 抑制因素
- DME處理成本高
- 機會
- 更多引進新的先進治療方案
- 完善 DME 治療的報銷政策和醫療保險
- 任務
- 設計 DME 治療臨床試驗的挑戰
- 促進因素
- 市場區隔分析
- 市場趨勢分析
- 高通膨的累積效應
- 波特五力分析
- 價值鍊和關鍵路徑分析
- 法律規範
第6章糖尿病黃斑部水腫治療市場（依治療）
- 皮質類固醇注射
- 藥物
- 雷射治療
- 藥物治療
第7章糖尿病黃斑部水腫治療市場：依最終使用者分類
- 醫院
- 眼科診所
第8章北美和南美糖尿病性黃斑部水腫治療市場
- 阿根廷
- 巴西
- 加拿大
- 墨西哥
- 美國
第9章亞太地區糖尿病性黃斑部水腫治療市場
- 澳洲
- 中國
- 印度
- 印尼
- 日本
- 馬來西亞
- 菲律賓
- 新加坡
- 韓國
- 台灣
- 泰國
- 越南
第10章歐洲、中東和非洲的糖尿病黃斑部水腫治療市場
- 丹麥
- 埃及
- 芬蘭
- 法國
- 德國
- 以色列
- 義大利
- 荷蘭
- 奈及利亞
- 挪威
- 波蘭
- 卡達
- 俄羅斯
- 沙烏地阿拉伯
- 南非
- 西班牙
- 瑞典
- 瑞士
- 土耳其
- 阿拉伯聯合大公國
- 英國
第11章競爭形勢
- FPNV定位矩陣
- 市場佔有率分析：主要企業
- 主要企業競爭情境分析
第12章競爭產品組合
- 主要公司簡介
- AbbVie Inc.
- Adverum Biotechnologies
- Aerpio Pharmaceuticals
- Alcon Vision LLC
- Alimera Sciences, Inc.
- Arctic Vision
- Bausch & Lomb Incorporated
- Chugai Pharmaceutical Co., Ltd.
- EyePoint Pharmaceuticals Inc. .
- F. Hoffmann-La Roche Ltd.
- Genentech, Inc.
- GlaxoSmithKline PLC
- Graybug Vision, Inc.
- KalVista Pharmaceuticals, Inc.
- Kodiak Sciences Inc
- Kubota Pharmaceutical Holdings Co. Ltd.
- Novartis AG
- Ocugen Inc.
- Oculis Holding AG
- Ocuphire Pharma, Inc.
- Oxurion NV
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc
- Teva Pharmaceutical Industries Ltd.
- YD Life Science
- 主要產品系列
第13章附錄
- 討論指南
- 關於許可證和定價
Product Code: MRR-2A0283E256C1
[198 Pages Report] The Diabetic Macular Edema Treatment Market size was estimated at USD 2.97 billion in 2023 and expected to reach USD 3.12 billion in 2024, at a CAGR 5.11% to reach USD 4.22 billion by 2030.
Global Diabetic Macular Edema Treatment Market
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 2.97 billion |
| Estimated Year [2024] | USD 3.12 billion |
| Forecast Year [2030] | USD 4.22 billion |
| CAGR (%) | 5.11% |
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Diabetic Macular Edema Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Diabetic Macular Edema Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Diabetic Macular Edema Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adverum Biotechnologies, Aerpio Pharmaceuticals, Alcon Vision LLC, Alimera Sciences, Inc., Arctic Vision, Bausch & Lomb Incorporated, Chugai Pharmaceutical Co., Ltd., EyePoint Pharmaceuticals Inc. ., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Graybug Vision, Inc., KalVista Pharmaceuticals, Inc., Kodiak Sciences Inc, Kubota Pharmaceutical Holdings Co. Ltd., Novartis AG, Ocugen Inc., Oculis Holding AG, Ocuphire Pharma, Inc., Oxurion NV, Pfizer Inc., Regeneron Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd., and YD Life Science.
Market Segmentation & Coverage
This research report categorizes the Diabetic Macular Edema Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Treatment
- Corticosteroid Injections
- Drugs
- Laser Treatment
- Pharmacological Treatment
- End-User
- Hospitals
- Ophthalmology Clinics
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Diabetic Macular Edema Treatment Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Diabetic Macular Edema Treatment Market?
3. What are the technology trends and regulatory frameworks in the Diabetic Macular Edema Treatment Market?
4. What is the market share of the leading vendors in the Diabetic Macular Edema Treatment Market?
5. Which modes and strategic moves are suitable for entering the Diabetic Macular Edema Treatment Market?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
- 4.1. Introduction
- 4.2. Diabetic Macular Edema Treatment Market, by Region
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising global prevalence of diabetes with increasing geriatric population
- 5.1.1.2. Increasing awareness of diabetic retinopathy and diabetic macular edema
- 5.1.1.3. Government-led initiatives to raise awareness about diabetic retinopathy
- 5.1.2. Restraints
- 5.1.2.1. High treatment costs of DME treatments
- 5.1.3. Opportunities
- 5.1.3.1. Increasing introduction of new and advanced treatment options
- 5.1.3.2. Improved reimbursement policies and healthcare coverage for DME treatments
- 5.1.4. Challenges
- 5.1.4.1. Clinical trial design challenges for DME treatments
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
6. Diabetic Macular Edema Treatment Market, by Treatment
- 6.1. Introduction
- 6.2. Corticosteroid Injections
- 6.3. Drugs
- 6.4. Laser Treatment
- 6.5. Pharmacological Treatment
7. Diabetic Macular Edema Treatment Market, by End-User
- 7.1. Introduction
- 7.2. Hospitals
- 7.3. Ophthalmology Clinics
8. Americas Diabetic Macular Edema Treatment Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
9. Asia-Pacific Diabetic Macular Edema Treatment Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
10. Europe, Middle East & Africa Diabetic Macular Edema Treatment Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
11. Competitive Landscape
- 11.1. FPNV Positioning Matrix
- 11.2. Market Share Analysis, By Key Player
- 11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
- 12.1. Key Company Profiles
- 12.1.1. AbbVie Inc.
- 12.1.2. Adverum Biotechnologies
- 12.1.3. Aerpio Pharmaceuticals
- 12.1.4. Alcon Vision LLC
- 12.1.5. Alimera Sciences, Inc.
- 12.1.6. Arctic Vision
- 12.1.7. Bausch & Lomb Incorporated
- 12.1.8. Chugai Pharmaceutical Co., Ltd.
- 12.1.9. EyePoint Pharmaceuticals Inc. .
- 12.1.10. F. Hoffmann-La Roche Ltd.
- 12.1.11. Genentech, Inc.
- 12.1.12. GlaxoSmithKline PLC
- 12.1.13. Graybug Vision, Inc.
- 12.1.14. KalVista Pharmaceuticals, Inc.
- 12.1.15. Kodiak Sciences Inc
- 12.1.16. Kubota Pharmaceutical Holdings Co. Ltd.
- 12.1.17. Novartis AG
- 12.1.18. Ocugen Inc.
- 12.1.19. Oculis Holding AG
- 12.1.20. Ocuphire Pharma, Inc.
- 12.1.21. Oxurion NV
- 12.1.22. Pfizer Inc.
- 12.1.23. Regeneron Pharmaceuticals Inc
- 12.1.24. Teva Pharmaceutical Industries Ltd.
- 12.1.25. YD Life Science
- 12.2. Key Product Portfolio
13. Appendix
- 13.1. Discussion Guide
- 13.2. License & Pricing
LIST OF FIGURES
- FIGURE 1. DIABETIC MACULAR EDEMA TREATMENT MARKET RESEARCH PROCESS
- FIGURE 2. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2023 VS 2030
- FIGURE 3. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. DIABETIC MACULAR EDEMA TREATMENT MARKET DYNAMICS
- FIGURE 7. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
- FIGURE 8. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 10. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 12. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 14. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. DIABETIC MACULAR EDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 20. DIABETIC MACULAR EDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
LIST OF TABLES
- TABLE 1. DIABETIC MACULAR EDEMA TREATMENT MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 6. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 7. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 8. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY LASER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 11. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 13. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 14. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 15. AMERICAS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 16. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 17. ARGENTINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 18. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 19. BRAZIL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 20. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 21. CANADA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 22. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 23. MEXICO DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 24. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 25. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 26. UNITED STATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 27. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 28. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 29. ASIA-PACIFIC DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 30. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 31. AUSTRALIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 32. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 33. CHINA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 34. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 35. INDIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 36. INDONESIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 37. INDONESIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 38. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 39. JAPAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 40. MALAYSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 41. MALAYSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 42. PHILIPPINES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 43. PHILIPPINES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 44. SINGAPORE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 45. SINGAPORE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 46. SOUTH KOREA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 47. SOUTH KOREA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 48. TAIWAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 49. TAIWAN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 50. THAILAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 51. THAILAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 52. VIETNAM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 53. VIETNAM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 54. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 55. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 56. EUROPE, MIDDLE EAST & AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 57. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 58. DENMARK DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 59. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 60. EGYPT DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 61. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 62. FINLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 63. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 64. FRANCE DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 65. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 66. GERMANY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 67. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 68. ISRAEL DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 69. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 70. ITALY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 71. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 72. NETHERLANDS DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 73. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 74. NIGERIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 75. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 76. NORWAY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 77. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 78. POLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 79. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 80. QATAR DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 81. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 82. RUSSIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 83. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 84. SAUDI ARABIA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 85. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 86. SOUTH AFRICA DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 87. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 88. SPAIN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 89. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 90. SWEDEN DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 91. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 92. SWITZERLAND DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 93. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 94. TURKEY DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 95. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 96. UNITED ARAB EMIRATES DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 97. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
- TABLE 98. UNITED KINGDOM DIABETIC MACULAR EDEMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 99. DIABETIC MACULAR EDEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
- TABLE 100. DIABETIC MACULAR EDEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 101. DIABETIC MACULAR EDEMA TREATMENT MARKET LICENSE & PRICING
